ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

3:00PM-4:30PM: Abstract Number: 0872

Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

3:00PM-4:30PM: Abstract Number: 0831

JDM Proteomic Signature at Disease Onset and Progression Highlights Persistent Dysregulation of Cell Death, Redox and Innate Immune Signaling

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0853

Lung Ultrasound in Rheumatoid Arthritis and Systemic Sclerosis: Accuracy of B-line and Pleural Assessment

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0836

NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0833

Novel Loss of Function Variants in the Death Domain of Tumor Necrosis Factor Superfamily Receptor 1A (TNFRSF1A) in Children with Systemic Juvenile Idiopathic Arthritis (sJIA)

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0864

Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

3:00PM-4:30PM: Abstract Number: 0847

Sex and Race-Specific Distributions in Medial Fixed Joint Space Width in Healthy Knees from Three Longitudinal Cohorts

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0832

Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs

Abstracts: Pediatric Rheumatology – Basic Science

3:00PM-4:30PM: Abstract Number: 0861

Stem Cell Function and Capsule Tissue Composition Are Associated with Symptoms, Joint Range of Motion and Radiographic Severity in People with Knee Osteoarthritis

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

3:00PM-4:00PM: Abstract Number: PP14

Support Groups and Chronic Illness: Finding Social Support Among Peers

Patient Perspectives

3:00PM-4:30PM: Abstract Number: 0875

Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

3:00PM-4:30PM: Abstract Number: 0863

The Development of Future Radiographic Knee Osteoarthritis Can Be Predicted by Peripheral Blood Epigenetic Models

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

3:00PM-4:30PM: Abstract Number: 0870

The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)

3:00PM-4:30PM: Abstract Number: 0842

The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)

Abstracts: Antiphospholipid Syndrome

3:00PM-4:30PM: Abstract Number: 0838

The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS

Abstracts: Antiphospholipid Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].